Generate Biomedicines Inc (NASDAQ:GENB) Receives $25.00 Average PT from Brokerages

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have earned an average rating of “Buy” from the five research firms that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $25.00.

A number of brokerages have recently commented on GENB. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research note on Tuesday. They issued an “overweight” rating for the company. Guggenheim initiated coverage on Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a research report on Tuesday. They issued a “buy” rating and a $26.00 target price for the company. Piper Sandler started coverage on Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating and a $24.00 price target on the stock. Finally, Morgan Stanley assumed coverage on Generate Biomedicines in a report on Tuesday. They set an “overweight” rating and a $20.00 price target on the stock.

Generate Biomedicines Price Performance

Shares of Generate Biomedicines stock opened at $12.85 on Tuesday. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.